isn’t that what we are up against have we all got out heads in the sand , are we all just living on hope the point is the trials failed their end points so they failed. The fda don’t have a great history of approval for failed endpoints secondary end points indicate a new trial should be conducted with revised end points . Is it that simple we will need to do more trials.As much as we hope and pray all likely good is we need more data . Years away now
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-183
-
- There are more pages in this discussion • 241 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |